Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6,763 | 2 | 45.6% |
| Consulting Fee | $5,725 | 2 | 38.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,180 | 3 | 14.7% |
| Food and Beverage | $178.06 | 2 | 1.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $6,763 | 2 | $0 (2022) |
| Janssen Research & Development, LLC | $5,725 | 2 | $0 (2017) |
| PFIZER INC. | $2,180 | 3 | $0 (2018) |
| Davol Inc. | $149.95 | 1 | $0 (2024) |
| Amgen Inc. | $28.11 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $178.06 | 2 | Davol Inc. ($149.95) |
| 2022 | $5,771 | 1 | Celgene Corporation ($5,771) |
| 2021 | $992.25 | 1 | Celgene Corporation ($992.25) |
| 2018 | $700.00 | 1 | PFIZER INC. ($700.00) |
| 2017 | $7,205 | 4 | Janssen Research & Development, LLC ($5,725) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Davol Inc. | Channel Drain (Device) | Food and Beverage | In-kind items and services | $149.95 | General |
| Category: Surgery | ||||||
| 09/03/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/08/2022 | Celgene Corporation | — | — | Cash or cash equivalent | $5,771.00 | Research |
| Study: (CC-99677-AS-001) Phase 2 Ankylosing Spondylitis | ||||||
| 08/19/2021 | Celgene Corporation | — | — | Cash or cash equivalent | $992.25 | Research |
| Study: A Phase 2a multicenter trial of CC-99677 in modera | ||||||
| 04/10/2018 | PFIZER INC. | ENBREL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $700.00 | General |
| Category: DERMATOLOGY;INFLAMMATION;PAIN | ||||||
| 11/22/2017 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 09/05/2017 | PFIZER INC. | ENBREL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $780.00 | General |
| Category: DERMATOLOGY;INFLAMMATION;PAIN | ||||||
| 05/16/2017 | PFIZER INC. | ENBREL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $700.00 | General |
| Category: DERMATOLOGY;INFLAMMATION;PAIN | ||||||
| 04/04/2017 | Janssen Research & Development, LLC | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $4,225.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| (CC-99677-AS-001) Phase 2 Ankylosing Spondylitis | Celgene Corporation | $5,771 | 1 |
| A Phase 2a multicenter trial of CC-99677 in modera | Celgene Corporation | $992.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 131 | 184 | $43,859 | $10,942 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 35 | 52 | $15,215 | $4,151 | 27.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 50 | 79 | $17,143 | $3,702 | 21.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 46 | 53 | $11,501 | $3,089 | 26.9% |
About Dr. Daniel Clegg, MD
Dr. Daniel Clegg, MD is a Rheumatology healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275623860.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Clegg, MD has received a total of $14,846 in payments from pharmaceutical and medical device companies, with $178.06 received in 2024. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "" ($6,763).
As a Medicare-enrolled provider, Clegg has provided services to 131 Medicare beneficiaries, totaling 184 services with total Medicare billing of $10,942. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Practice Information
- Specialty Rheumatology
- Location Salt Lake City, UT
- Active Since 10/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1275623860
Products in Payments
- STELARA (Biological) $5,725
- ENBREL (Biological) $2,180
- Channel Drain (Device) $149.95
- UPLIZNA (Biological) $28.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Salt Lake City
Curry Koening, M.d, M.D
Rheumatology — Payments: $40,179
Dr. Grant Cannon, M.d, M.D
Rheumatology — Payments: $6,819
Tawnie Braaten, M.d, M.D
Rheumatology — Payments: $871.32
Dr. Javier Rios, Md, MD
Rheumatology — Payments: $712.71
Swetha Ann Alexander, Mbbs, MBBS
Rheumatology — Payments: $316.64
Dr. Julie Thomas, M.d, M.D
Rheumatology — Payments: $157.53